Verona Pharma plc (VRNA)
After hours:
| Previous Close | 16.20 |
| Open | 16.49 |
| Bid | 16.33 x 100 |
| Ask | 16.48 x 100 |
| Day's Range | 16.00 - 16.52 |
| 52 Week Range | 11.83 - 23.81 |
| Volume | |
| Avg. Volume | 444,080 |
| Market Cap | 1.27B |
| Beta (5Y Monthly) | 0.41 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.72 |
| Earnings Date | May 07, 2024 - May 11, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 33.86 |
GlobeNewswireAndrew Fisher Joins Verona Pharma as General Counsel
LONDON and RALEIGH, N.C., March 04, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces Mr. Andrew Fisher has today joined the Company as General Counsel, and member of the Executive Management Team. Mr. Fisher is an accomplished lawyer with more than 25 years of experience in the life sciences industry. He brings a wealth of legal and strategic expertise supporting global, pre-clinical and clinical development, manufacturing and commercializat
Insider MonkeyVerona Pharma plc (NASDAQ:VRNA) Q4 2023 Earnings Call Transcript
Verona Pharma plc (NASDAQ:VRNA) Q4 2023 Earnings Call Transcript February 29, 2024 Verona Pharma plc beats earnings expectations. Reported EPS is $-0.18, expectations were $-0.23. VRNA isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to Verona Pharma’s Fourth Quarter […]
- GuruFocus.com
Verona Pharma PLC Reports Fourth Quarter and Full Year 2023 Financial Results
VRNA Prepares for Potential Commercial Launch with Strong Financial Position
